Retro Biosciences, a longevity startup funded by Sam Altman, is currently testing a new pill called RTR 242, which aims to enhance cellular recycling processes and potentially combat dementia-related diseases like Alzheimer’s and Parkinson’s. The company has expanded its clinical trials in Australia, increasing participant enrollment by over 42% due to the absence of severe side effects, which has made it challenging to determine the optimal dosage for effectiveness. Retro’s approach focuses on restoring the function of lysosomes—cellular structures that degrade waste—which tend to malfunction as we age. As Retro aims to lead the race for a breakthrough longevity drug in Silicon Valley, other companies are pursuing similar targets, but Retro’s human trials may give it a competitive edge.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.businessinsider.com/retro-biotech-testing-higher-doses-of-rtr-242-alzheimers-drug-2026-8
